Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer
| Autor: | Cristina Saiz-Ladera, Mariona Baliu-Piqué, Francisco J. Cimas, Aránzazu Manzano, Vanesa García-Barberán, Santiago Cabezas Camarero, Gonzalo Fernández Hinojal, Atanasio Pandiella, Balázs Győrffy, David Stewart, Juan J. Cruz-Hernández, Pedro Pérez-Segura, Alberto Ocana |
|---|---|
| Přispěvatelé: | Instituto de Salud Carlos III, Acepain Albacete, Diputación de Albacete, Fundación CRIS contra el Cáncer, Ministerio de Economía y Competitividad (España), Asociación Española Contra el Cáncer, European Commission |
| Rok vydání: | 2021 |
| Předmět: |
Human papillomavirus
Cancer Research Cell head and neck squamous cell carcinoma (HNSCC) Cervical squamous cell carcinoma (CSCC) Immunologic activation Transcriptome Immune system cervical squamous cell carcinoma (CSCC) medicine human papillomavirus Transcriptome signature Lung cancer RC254-282 Original Research Cervical cancer Lung business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Head and neck squamous cell carcinoma (HNSCC) medicine.disease Head and neck squamous-cell carcinoma transcriptome signature immune gene signatures stomatognathic diseases medicine.anatomical_structure Oncology Immune gene signatures Cancer research business |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname Frontiers in Oncology Frontiers in Oncology, Vol 11 (2021) |
| ISSN: | 2234-943X |
| Popis: | © 2021 Saiz-Ladera, Baliu-Piqué, Cimas, Manzano, García-Barberán, Camarero, Hinojal, Pandiella, Győrffy, Stewart, Cruz-Hernández, Pérez-Segura and Ocana. Targeting the immune system has emerged as an effective therapeutic strategy for the treatment of various tumor types, including Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-small-Cell Lung Cancer (NSCLC), and checkpoint inhibitors have shown to improve patient survival in these tumor types. Unfortunately, not all cancers respond to these agents, making it necessary to identify responsive tumors. Several biomarkers of response have been described and clinically tested. As of yet what seems to be clear is that a pre-activation state of the immune system is necessary for these agents to be efficient. In this study, using established transcriptomic signatures, we identified a group of gene combination associated with favorable outcome in HNSCC linked to a higher presence of immune effector cells. CD2, CD3D, CD3E, and CXCR6 combined gene expression is associated with improved outcome of HNSCC patients and an increase of infiltrating immune effector cells. This new signature also identifies a subset of cervical squamous cell carcinoma (CSCC) patients with favorable prognosis, who show an increased presence of immune effector cells in the tumor, which outcome shows similarities with the HP-positive HNSCC cohort of patients. In addition, CD2, CD3D, CD3E, and CXCR6 signature is able to predict the best favorable prognosis in terms of overall survival of CSSC patients. Of note, these findings were not reproduced in other squamous cell carcinomas like esophageal SCC or lung SCC. Prospective confirmatory studies should be employed to validate these findings. This work has been supported by Instituto de Salud Carlos III (PI16/01121 and PI19/00808), ACEPAIN; Diputación de Albacete, CIBERONC and CRIS Cancer Foundation (to AO). Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R), the Instituto de Salud Carlos III through the Spanish Cancer Centers Network Program (RD12/0036/0003) and CIBERONC, the scientific foundation of the AECC and the CRIS Foundation (to AP). The work carried out in our laboratories receive support from the European Community through the regional development funding program (FEDER). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|